Methyldopa Pharmapoint Uk (Methyldopa)

Methyldopa is metabolised to alpha‑methylnorepinephrine, which activates central alpha‑2 adrenergic receptors. This reduces sympathetic outflow from the brain, decreasing norepinephrine release, lowering peripheral vascular resistance and consequently reducing arterial blood pressure.

The appropriate dose of methyldopa is determined by the prescribing clinician based on the individual’s blood‑pressure profile, age, renal and hepatic function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Methyldopa is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no well‑controlled human studies. It is often preferred for managing hypertension in pregnancy, but clinicians should evaluate each case. Limited data are available for breastfeeding; the decision should be made with professional guidance.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Methyldopa belongs to the alpha‑2 adrenergic agonist class, differing from ACE inhibitors, calcium‑channel blockers or diuretics. It is particularly useful in pregnancy because it has a long safety record, whereas many other antihypertensives are contraindicated or less studied in this population.

Store the product at room temperature, preferably below 25 °C. Keep it in the original packaging to protect from moisture and light. Do not refrigerate or freeze the tablets unless the label specifically advises otherwise.

Methyldopa is taken orally, usually with food or a glass of water to reduce stomach irritation. The tablet should be swallowed whole; it should not be crushed, chewed, or dissolved unless a healthcare professional advises otherwise.

Serious risks include severe hypotension, liver dysfunction, and hemolytic anemia. Patients should be monitored for signs of sudden blood‑pressure drops, jaundice, dark urine, or unexplained fatigue, and report these symptoms to their healthcare provider promptly.

Methyldopa is contraindicated in patients with known hypersensitivity to the drug, severe liver disease, or those taking monoamine oxidase inhibitors. Caution is also advised for individuals with a history of depression or those who are pregnant without medical supervision.